Original articleClinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy
Section snippets
Methods
Two cohorts were reviewed in this large retrospective case series: 75 infants treated with IVB in the BEAT-ROP clinical trial (Clinicaltrials.gov trial identifier, NCT00622726) from March 13, 2008, through August 4, 2010,12 and 218 infants treated consecutively with IVB (by H.M.H.) after the BEAT-ROP clinical trial who were treated and followed up at the Memorial Hermann Hospital System, Houston, Texas, and at the hospitals in Webster, Corpus Christi, and El Paso, Texas, from August 5, 2010,
Results
A total of 241 infants (471 eyes, i.e., 11 unilateral cases) treated with IVB monotherapy for ROP in zones I or II posterior were eligible for review in this study (55 infants from the BEAT-ROP clinical trial and 186 infants treated after the BEAT-ROP clinical trial). Thirty-one infants without follow-up examinations extending to 65 weeks were excluded from analysis, as well as 21 infants who had died before 65 weeks.
The demographics, infant characteristics, and initial treatment information
Discussion
There have been several case reports of late recurrence after treatment of stage 3+ ROP or APROP with IVB monotherapy27, 28 and after combined treatment using laser therapy with intravitreal ranibizumab29 or with IVB.27, 30, 31, 32 In each of these reports, close follow-up (every 1 or 3 weeks) was not performed beyond 55 weeks AA; however, standard follow-up recommendations have not been established by ophthalmologic studies reviewing prospective data. Also, not surprisingly, there are reports
References (39)
- et al.
Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010
Pediatr Res
(2013) Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results
Arch Ophthalmol
(1988)Revised indications for the treatment of retinopathy of prematurity
Arch Ophthalmol
(2003)Ocular neovascularization. The Krill Memorial Lecture
Am J Ophthalmol
(1978)- et al.
The demonstration of angiogenic activity from ocular tissues. Preliminary report
Ophthalmology
(1980) - et al.
Vitamin E protects against retinopathy of prematurity through action on spindle cells
Nature
(1984) - et al.
Vascular endothelial growth factor is a secreted angiogenic mitogen
Science
(1989) - et al.
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
N Engl J Med
(1994) - et al.
Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity
Mol Vis
(2008) - et al.
Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity
Invest Ophthalmol Vis Sci
(2014)
Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity
Indian J Ophthalmol
Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity: preliminary results of the BEAT-ROP clinical trial
N Engl J Med
Visual field extent at 6 years of age in children who had high-risk prethreshold retinopathy of prematurity
Arch Ophthalmol
Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings at 4 to 6 years of age
J AAPOS
Anterior segment abnormalities in cicatricial retinopathy of prematurity
Ophthalmology
Case series of angle-closure glaucoma after laser treatment for retinopathy of prematurity
J AAPOS
Intravitreal bevacizumab for retinopathy of prematurity: refractive error results
Am J Ophthalmol
Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial
JAMA Ophthalmol
Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes
Eye
Cited by (138)
Fundus fluorescein angiography imaging of retinopathy of prematurity in infants: A review
2023, Survey of OphthalmologyRetinopathy of prematurity: A review of pathophysiology and signaling pathways
2023, Survey of OphthalmologyCitation Excerpt :It was approved for cancer therapy but is used off-label for eye diseases.403 Although it has shown an advantage over laser therapy for ROP stage 3 with plus disease in zone I but not in zone II, recurrence of ROP is not uncommon.167,255,256 In addition, bevacizumab has been associated with several serious adverse outcomes in clinical studies.15,96
See Editorial on page 1843.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (grant no.: P30EY010608; Research to Prevent Blindness, Inc, New York, New York (Challenge Grant to The University of Texas Health Science Center at Houston McGovern Medical School); the National Center for Research Resources, National Institutes of Health, Bethesda, Maryland (grant no.: UL1 RR024148); Alfred W. Lasher III Research Funds to The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas; and the Hermann Eye Fund, Houston, Texas. The funding organizations had no role in the design or conduct of this research.
Author Contributions:
Conception and design: Mintz-Hittner, Chuang
Analysis and interpretation: Mintz-Hittner, Geloneck
Data collection: Mintz-Hittner, Geloneck
Obtained funding: none
Overall responsibility: Mintz-Hittner, Geloneck, Chuang